The NHS Institute for Innovation and Improvement has released two new Better Care, Better Value indicators and revised the existing low cost statin indicator.
The existing indicator details the proportion of statin prescribing that consisted of low cost statins, namely simvastatin and pravastatin. This has been revised to now include ezetimibe in the denominator. The reports can be accessed online.
The two new indicators analyse low cost prescribing for drugs affecting the renin-angiotensin system and low cost proton pump inhibitors. The former measures the number of prescriptions written for angiotensin converting enzyme (ACE) inhibitors (excluding combination products) as a proportion of all drugs affecting the renin-angiotensin system. The latter measures the number of prescriptions for low cost proton pump inhibitors (PPIs), namely omeprazole and lansoprazole but excluding Losec MUPS® and Zoton FasTabs®, as a proportion of all prescriptions for PPIs.
Action: Clinicians should already aware of the cost differences in these indicator areas and the potential for improved cost-efficiency. The introduction of these new indicators is likely to increase the focus on these areas of prescribing.